Anti-Angiogenic Therapies for Children with Cancer

被引：8

作者：

Andre, N. ^{[1
,2
]}

Verschuur, A. ^{[1
]}

Rossler, J. ^{[3
]}

Sterba, J. ^{[4
]}

机构：

[1] Hop Enfants La Timone, Serv Oncol Pediat, Marseille, France

[2] Univ Aix Marseille, UMR INSERM 911, Ctr Rech Oncol Biol & Oncopharmacol CRO2, Marseille, France

[3] Univ Hosp Freiburg, Div Pediat Hematol Oncol, Dept Pediat & Adolescent Med, Freiburg, Germany

[4] Univ Hosp Brno, Dept Pediat Oncol, Brno, Czech Republic

来源：

CURRENT CANCER DRUG TARGETS | 2010年 / 10卷 / 08期

关键词：

Children; oncology; angiogenesis; treatment; metronomic; VEGF; Tyrosine kinase inhibitors; ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; PRECLINICAL TESTING PROGRAM; HUMAN NEUROBLASTOMA-CELLS; RECURRENT SOLID TUMORS; HIGH-DOSE CHEMOTHERAPY; NERVOUS-SYSTEM TUMORS; POTENT VEGF BLOCKADE; PHASE-I TRIAL; METRONOMIC CHEMOTHERAPY;

D O I：

10.2174/156800910793357899

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Tumor angiogenesis, i.e. the development of neovascularisation in and around solid tumors, plays a key role in the local and distant growth of cancer and anti-angiogenic treatments are now established strategies to treat cancer patients. Specific inhibitors of angiogenesis such as bevacizumab or receptor tyrosine kinase inhibitors targeting VEGFR or PDGFR are now in clinical trials and are being increasingly validated for the treatment of poor prognostic cancers. Other anti-angiogenic strategies such as cilengitide or metronomic chemotherapy (low-dose anti-angiogenic chemotherapy) have been developed to treat certain types of adult cancer. In children, the clinical potential of anti-angiogenic approach is still in an early stage of investigation. This review will focus on the role of angiogenesis in pediatric solid tumors and will describe the pre-clinical and clinical experience with several anti-angiogenic compounds as a potential treatment for children with cancer.

引用

页码：879 / 889

页数：11

共 114 条

[1]

Increased microvascular density predicts relapse in Wilms' tumor [J].

Abramson, LP ;

Grundy, PE ;

Rademaker, AW ;

Helenowski, I ;

Cornwell, M ;

Katzenstein, HM ;

Reynolds, M ;

Arensman, RM ;

Crawford, SE .

JOURNAL OF PEDIATRIC SURGERY, 2003, 38 (03) :325-329

[2]

Targeting multiple signal transduction pathways in lung cancer [J].

Adjei, Alex A. .

CLINICAL LUNG CANCER, 2005, 7 :S39-S44

[3]

Aguilera Dolly, 2008, Sarcoma, V2008, P261589, DOI 10.1155/2008/261589

[4]

Metronomic etoposide/cyclophospliamide/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study [J].

Andre, Nicolas ;

Rome, Angelique ;

Coze, Carole ;

Paclovani, Laetitia ;

Pasquier, Eddy ;

Camoin, Laurence ;

Gentet, Jean Claude .

CLINICAL THERAPEUTICS, 2008, 30 (07) :1336-1340

[5]

For cancer, seek and destroy or live and let live? [J].

Andre, Nicolas ;

Pasquier, Eddy .

NATURE, 2009, 460 (7253) :324-324

[6]

Response to 'Intermittent androgen blockade should be regarded as standard therapy in prostate cancer' [J].

Andre, Nicolas ;

Pasquier, Eddy .

NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02) :E1-E2

[7]

Arasteh K, 2000, Oncologist, V5 Suppl 1, P28

[8]

Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma [J].

Bäckman U. ;

Svensson Å. ;

Christofferson R. .

Angiogenesis, 2002, 5 (4) :267-274

[9]

Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A children's oncology group study [J].

Bender, Julia L. Glade ;

Adamson, Peter C. ;

Reid, Joel M. ;

Xu, Lu ;

Baruchel, Sylvain ;

Shaked, Yuval ;

Kerbel, Robert S. ;

Cooney-Qualter, Erin M. ;

Stempak, Diana ;

Chen, Helen X. ;

Nelson, Marvin D. ;

Krailo, Mark D. ;

Ingle, Ashish M. ;

Blaney, Susan M. ;

Kandel, Jessica J. ;

Yamashiro, Darrell J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :399-405

[10]

Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors [J].

Benesch, M. ;

Windelberg, M. ;

Sauseng, W. ;

Witt, V. ;

Fleischhack, G. ;

Lackner, H. ;

Gadner, H. ;

Bode, U. ;

Urban, C. .

ANNALS OF ONCOLOGY, 2008, 19 (04) :807-813

← 1 2 3 4 5 6 7 8 9 10 →